BBEU - ETF AI Analysis
Top Page
JPMorgan BetaBuilders Europe ETF (BBEU)
BBEU, the JPMorgan BetaBuilders Europe ETF, has a solid overall rating driven by high-quality European blue chips like Novartis, HSBC, and AstraZeneca, which show strong financial performance, positive earnings outlooks, and generally supportive technical trends. Additional support comes from leaders such as ASML and TotalEnergies, though some holdings like SAP, with bearish technical signals and valuation concerns, and others facing overvaluation or growth challenges, slightly weigh on the fund. The main risk is its concentration in European markets and large established companies, which ties performance closely to Europe’s economic and regulatory environment.
BBEU vs. SPDR S&P 500 ETF (SPY)
- AUM
- 9.09B
- Region
- Europe
- Expense Ratio
- 0.09%
- Beta
- 0.67
- Issuer
- JPMorgan
- Inception Date
- Jun 15, 2018
- Dividend Yield
- 3.01%
- Asset Class
- Equity
- Index Tracked
- Morningstar Developed Europe Target Market Exposure Index
BBEU Summary
BBEU is the JPMorgan BetaBuilders Europe ETF, designed to follow the Morningstar Developed Europe Target Market Exposure Index. It gives you broad access to European stocks across many countries and sectors in a single investment. The fund holds well-known companies like Nestlé, HSBC, Shell, and Novartis, mixing large, established firms with smaller ones. Someone might invest in BBEU to diversify beyond the U.S. and tap into Europe’s long-term growth potential. A key risk is that European stock prices can go up and down with global markets and currency swings, so your investment value may fluctuate.
How much will it cost me?
This ETF has an expense ratio of 0.09%, which means you’ll pay about $0.90 per year for every $1,000 invested. That’s lower than the average ETF because it’s a passively managed fund that simply tracks a broad European market index instead of paying managers to pick individual stocks.
What would affect this ETF?
BBEU could benefit if European economies grow steadily, supporting its broad mix of sectors and major holdings like ASML, Nestlé, and large banks, and if global demand for healthcare, consumer staples, and industrial technology remains strong. On the downside, slower economic growth in developed Europe, banking or energy sector stress, or regulatory changes affecting big European companies could weigh on the fund’s performance.
BBEU Top 10 Holdings
BBEU leans heavily on Europe’s blue-chip leaders, with chipmaker ASML acting as a key engine for long-term gains even after some recent wobbling. Health care giants Roche and Novartis are steadily pulling their weight, giving the fund a defensive backbone, while AstraZeneca is losing a bit of steam and slightly dampening returns. On the value side, Shell and TotalEnergies have been rising, helping offset softer names like HSBC and Siemens. Overall, it’s a developed Europe story, diversified across sectors but anchored in a handful of large, globally known champions.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 4.79% | $434.06M | EUR 539.67B | 50.70% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 GB:SHEL | Shell (UK) | 2.33% | $211.15M | GBP 229.30B | 40.01% | 73Outperform |
 GB:HSBA | HSBC Holdings | 2.20% | $199.28M | GBP 218.81B | 19.37% | 80Outperform |
 CH:NOVN | Novartis AG | 2.27% | $205.73M | CHF 244.89B | 35.30% | 80Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 CH:NESN | Nestlé SA | 1.86% | $168.56M | CHF 217.87B | 9.36% | 71Outperform |
 DE:SAP | SAP SE | 1.66% | $150.93M | EUR 246.65B | -6.46% | 66Neutral |
 DE:SIE | Siemens | 1.64% | $148.32M | EUR 202.50B | 7.55% | 74Outperform |
 FR:TTE | TotalEnergies SE | 1.42% | $128.64M | EUR 190.70B | 59.27% | 78Outperform |
BBEU Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBEU, the sentiment is Positive. The current price of 76.21 is above the 20-day moving average (MA) of 75.52, below the 50-day MA of 77.12, and above the 200-day MA of 75.94, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 50.88 is Neutral, neither overbought nor oversold. The STOCH value of 73.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBEU.
BBEU Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| BBEU | $76.21 | $82.00(7.60% Upside) | $9.09B | 0.09% | 64Neutral |
 IEUR | $74.40 | $87.90(18.14% Upside) | $9.55B | 0.09% | 63Neutral |
 EZU | $65.16 | $80.02(22.81% Upside) | $9.25B | 0.50% | 63Neutral |
 FEZ | $65.03 | $80.86(24.34% Upside) | $4.16B | 0.29% | 67Neutral |
 HEDJ | $55.68 | $66.24(18.97% Upside) | $1.73B | 0.58% | 60Neutral |
 IEV | $71.73 | $84.97(18.46% Upside) | $1.57B | 0.60% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BBEU | JPMorgan BetaBuilders Europe ETF | 76.21 | 8.17 | 12.01% | |
| IEUR | iShares Core MSCI Europe ETF | 74.40 | 8.18 | 12.36% | |
| EZU | iShares MSCI Eurozone ETF | 65.16 | 4.69 | 7.75% | |
| FEZ | SPDR EURO STOXX 50 ETF | 65.03 | 4.16 | 6.84% | |
| HEDJ | WisdomTree Europe Hedged Equity Fund | 55.68 | 4.81 | 9.46% | |
| IEV | iShares Europe ETF | 71.73 | 7.72 | 12.06% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.